Literature DB >> 27630210

Hypersensitivity Reaction Following Administration of Low-Dose Oral Vancomycin for the Treatment of Clostridium difficile in a Patient With Normal Renal Function.

Laura J Baumgartner1, Lauren Brown2, Curt Geier3.   

Abstract

Systemic absorption of oral vancomycin for the treatment of Clostridium difficile is thought to be trivial in patients without risk factors for increased systemic absorption and is often overlooked in clinical practice. A 51-year-old male elicits a suspected immunoglobulin E-mediated hypersensitivity following administration of low-dose oral vancomycin for the treatment of severe C difficile. The patient had normal renal function and was administered low doses of the medication, however, had a medical history significant for diverticulitis. Applying the Naranjo adverse drug reaction probability scale, a score of 5 was obtained, indicating a probable association between the administration of oral vancomycin and the hypersensitivity reaction. This case demonstrates that hypersensitivity reactions following low-dose oral vancomycin administration in patients with severe C difficile are possible, despite having normal renal function. Other risk factors for systemic absorption of oral vancomycin need to be evaluated in the literature, including severity of disease and underlying gastrointestinal processes.

Entities:  

Keywords:  Clostridium difficile; adverse reaction; oral vancomycin

Mesh:

Substances:

Year:  2016        PMID: 27630210     DOI: 10.1177/0897190016668437

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  2 in total

Review 1.  Glycopeptide Hypersensitivity and Adverse Reactions.

Authors:  Vanthida Huang; Nicola A Clayton; Kimberly H Welker
Journal:  Pharmacy (Basel)       Date:  2020-04-21

2.  Rash induced by enteral vancomycin therapy in an older patient in a long-term care ventilator unit: case report and review of the literature.

Authors:  Jeremy Barron; Adolfo Lattes; Esther-Lee Marcus
Journal:  Allergy Asthma Clin Immunol       Date:  2018-11-06       Impact factor: 3.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.